## **Supporting Information**

## Biomimetic Nanovesicles for Enhanced Antitumor Activity of Combinational Photothermal and Chemotherapy


Tingting Wu<sup>1</sup>, Dan Zhang<sup>1</sup>, Qi Qiao<sup>1</sup>, Xianya Qin<sup>1</sup>, Conglian Yang<sup>1</sup>, Miao Kong<sup>1</sup>, Huan Deng<sup>1</sup>, Zhiping Zhang<sup>1,2,3\*</sup>

HuaZhong University of Science and Technology, Wuhan, China 430030


<sup>&</sup>lt;sup>1</sup> Tongji School of Pharmacy

<sup>&</sup>lt;sup>2</sup> National Engineering Research Center for Nanomedicine

<sup>&</sup>lt;sup>3</sup> Hubei Engineering Research Center for Novel Drug Delivery System



**Figure S1.** The relative diameter change of NV-DOX and NV-DOX-DIR in FBS for 5 days (n = 3).



**Figure S2.** The relative retained DOX in NVs for 5 days at  $4 \, ^{\circ}$ C (n = 3).







Figure S3. Quantitative detection of ROS generation after treating with NIR irradiation (n = 3).




**Figure S4.** The quantitation of fluorescent intensity of tumors and the major organs at 48 h after intravenous injection of free DIR and NV-DIR (n = 3, \*p < 0.05).



**Figure S5.** The tumor inhibitory rate after treating with PBS+Laser, DOX, DOX+Laser, NV-DOX, NV-DIR+Laser and NV-DOX-DIR+Laser, respectively (n = 7, p < 0.05).



**Figure S6.** The relative body weight change after various treatments (n = 7)



**Figure S7.** The weight of the excised tumors after different treatments (n = 7, \*p < 0.05).